Bluebird bio Inc and Celgene Corp stock performance
Share of bluebird bio Inc (BLUE:NASDAQ) and Celgene Corp (CELG:NASDAQ) surged Monday after the companies announce "Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting". Some key highlighted are: Overal response rate (ORR) of 94% in patients and Complete Response (CR) rate of 56% from prior 27% in summer ASCO. Full press release here http://investor.bluebirdbio.com/news-releases/news-release-details/celgene-corporation-and-bluebird-bio-announce-updated-results
BLUE made new 52 weeks high today, then follow up with 600 million stock offering after hours. Here is how the stock performance for this year.
CELG stock has a decent year performance until it got hit by their 3Q earning reports updated from their OTEZLA® sales miss and weaker outlook. The company still have four other major drugs and the sales are still going strong.
Regardless, how these two stocks performance. It's great to see there are new biotech development drug to help cure and save patients life.